Search

everythinglearnresearchcommunity

for

Search:↓

PCOS causes menstrual issues, infertility, and long-term health risks.

All women with Polycystic Ovary Syndrome (PCOS) in a study had at least one skin disorder, with the most common being excessive hair growth, acne, dark skin patches, hair loss, and oily skin.

Certain gene variations might be linked to severe acne in women but not in men.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Testosterone therapy may slightly increase sexual desire in women with HSDD but lacks broad recommendation due to safety concerns and limited approval.

Women with keloid scars often have acne and hair loss, especially those with "true" keloids, indicating a possible hormonal imbalance.

The document concludes that effectively managing PCOS requires a multifaceted approach.

The chemicals 17βC and its methyl ester can block the effects of testosterone on hamster skin but not the effects of DHT.

Reversed sequential therapy with cyproterone acetate was effective for treating women with hirsutism and related conditions.

Topical drugs can target hair follicles to treat skin conditions more effectively.

Antiandrogens may help treat conditions like excessive hair growth, prostate tumors, male baldness, and acne by blocking male hormone effects.

The conclusion is that antibiotics are not the best acne treatment and early treatment is important to prevent scarring, especially for those with a family history of acne.

Most skin conditions can be managed with general medical knowledge.

New compounds can block testosterone effects in rats and might help treat conditions like prostate cancer and acne.

Human sebaceous glands contain enzymes that affect androgen production and may influence sebum production and acne.

Women with PCOS often experience anxiety, depression, and a lower quality of life.

Women with PCOS often have more body hair, acne, and skin darkening, and these signs are linked to metabolic issues like insulin resistance and high cholesterol.

Acne is not a key diagnostic feature for PCOS, postadolescent men with acne may have insulin resistance, melanoma patients often have few moles, tumor size in CSCC indicates higher risk of serious outcomes, and hidradenitis suppurativa is linked to higher risk of heart problems and death.

Excess male hormones in postmenopausal women can cause health issues and increase the risk of heart disease and diabetes; treatment depends on the cause.

Finasteride is more effective and satisfactory than montelukast for treating moderate acne in women.

New signs like changes in blood markers, physical symptoms, and behavioral shifts may help detect hidden steroid use in athletes.

Some skin conditions may indicate metabolic syndrome, which could help with early detection and management of related health issues.

PCOS in lean women is a serious health condition with implications beyond fertility, affecting metabolism and increasing cardiovascular disease risk.

The document concludes that managing female hyperandrogenism requires a combination of identifying the cause, lifestyle changes, medication, and cosmetic treatments.

The most common skin problems in polycystic ovarian disease are hirsutism and acne, and managing these symptoms is key for treatment.

High levels of fatty acids are linked to increased androgen production and inflammation in women with PCOS, which may affect IVF outcomes.

Acne patients have higher mTOR gene expression.

Antiandrogens help treat hormone-related conditions in both men and women.

The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.

The levonorgestrel implant increases free testosterone and lowers SHBG more than DMPA-IM and the copper IUD.